Fair Value Calculator Fair Value Calculator
EN DE

Farmaceutica REMEDIA S.A (RMAH) Fair Value & Analysis

Healthcare · RO · Market cap 74.0M RON

FR Farmaceutica REMEDIA S.A RMAH · RO
Price0.7900 RON
Fair Value1.72 RON
Upside+117.7%
Quality57/100
Watch Farmaceutica REMEDIA S.A for free, get notified when fair value or trend changes. Watch for free
Evidence: Medium Range 1.29 RON – 2.14 RON

Fair value as of: Jul 19, 2026

From 22 valuation models · updated today

Fair value updated Jul 19, 2026, revised from 2.55 RON to 1.72 RON (−32.5%) since Jun 24, 2026. Share price −11.8% over the past month.

Price vs Fair Value (12 months)

0.9380 RON 0.6568 RON Fair Value 1.72 RON Jun 2025 Jun 2026

12‑month range 0.6568 RON – 0.9380 RON · fair‑value band 1.29 RON – 2.14 RON · the 0.7900 RON price screens below the 1.72 RON fair value. As of Jul 19, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Farmaceutica REMEDIA S.A (RMAH) currently trades at 0.7900 RON, while our model-based Fair Value estimate is 1.72 RON, implying the stock looks roughly 117.7% undervalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Farmaceutica REMEDIA S.A generated revenue of 740M RON at a net margin of 0.8%. Revenue declined 10.9% year over year. It earns a return on equity of 7.5%. The stock trades on a trailing P/E of 9.9. Fundamentals as of Jul 19, 2026

Our scenario range runs from 1.29 RON (bear case) to 2.14 RON (bull case); at 0.7900 RON, the current price sits below that range. The share trades about 17% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 24% fair-value upside, at 118%, RMAH screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 740M RON
Revenue growth (YoY) -10.9%
Net margin 0.8%
Return on equity 7.5%
Free cash flow 15.5M RON FY2025
P/E ratio 9.9
More key figures
Operating margin 0.6%
EPS (TTM) 0.0800 RON
Dividend yield 6.3%
EPS growth (YoY) -76.3%

Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.

About the company

Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. It is also involved in the wholesale distribution of medicines to pharmacies, and public and private hospitals and clinics. In addition, the company provides packaging materials; and logistics and warehousing, promotion and marketing of drugs, and pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Farmaceutica REMEDIA S.A reported revenue of 760M RON in FY2025 versus 477M RON in FY2021, a compound +12.3%/yr. Reported net income was 8.0M RON in FY2025, compounding +2.7%/yr from FY2021.

Revenue +12.3%/yr
FY21 477M RON
FY22 536M RON
FY23 593M RON
FY24 744M RON
FY25 760M RON
Net income +2.7%/yr
FY21 7.2M RON
FY22 5.8M RON
FY23 7.2M RON
FY24 7.0M RON
FY25 8.0M RON

Is RMAH fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Farmaceutica REMEDIA S.A Fair Value". https://www.fairvalue-calculator.com/stock/RMAH

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation M1CK34 R$999.49 R$1,236 +24%
Cencora, Inc COR $270.32 $168.24 -38%
Cardinal Health, Inc CAH $201.74 $92.07 -54%
Sigma Healthcare Limited SIGGF $2.35 $0.7800 -67%
Henry Schein, Inc HSIC $78.85 $62.37 -21%
Shanghai Pharmaceuticals Holding 601607 ¥15.96 ¥45.15 +183%
Sinopharm Group 1099 HK$16.74 HK$61.33 +266%
Galenica AG GALNF $115.00 $98.28 -15%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥20.81 ¥30.70 +48%
Medipal Holdings MEPDF $18.35 $29.88 +63%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Farmaceutica REMEDIA S.A (RMAH) undervalued?
As of Jul 19, 2026, our model estimates a fair value of 1.72 RON versus a price of 0.7900 RON, about +118% (undervalued). Model-based estimate, not financial advice.
What is the fair value of RMAH?
Our model-based fair value for Farmaceutica REMEDIA S.A is 1.72 RON (as of Jul 19, 2026), built from audited fundamentals. The current price is 0.7900 RON.
What is the quality score of RMAH?
Farmaceutica REMEDIA S.A has a Quality Score of 57/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Farmaceutica REMEDIA S.A (RMAH)?
Farmaceutica REMEDIA S.A reported trailing-twelve-month revenue of about 740M RON (latest available figure, as of Jul 19, 2026).
What is the net profit margin of RMAH?
The net profit margin of Farmaceutica REMEDIA S.A is about 0.8%, meaning it keeps roughly 0.8% of revenue as net income. Based on the latest reported figures.
Does Farmaceutica REMEDIA S.A pay a dividend?
Farmaceutica REMEDIA S.A currently shows a dividend yield of about 6.31% relative to its recent price (as of Jul 19, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free alert · no account needed

Tell me when Farmaceutica REMEDIA S.A reaches its Fair Value

Just your email, and we'll notify you when the price and Fair Value of Farmaceutica REMEDIA S.A materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.